Skip to search formSkip to main contentSkip to account menu

retaspimycin hydrochloride

Known as: 17-Allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride, Geldanamycin, 18,21-didehydro-17-demethoxy-18,21-dideoxo-18,21-dihydroxy-17-(2-propenylamino)-, monohydrochloride 
The hydrochloride salt of a small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities… 
National Institutes of Health

Related topics

Related topics

5 relations
17-allylamino-17-demethoxygeldanamycin hydroquinoneHSP90 Heat-Shock ProteinsIPI 504Signal Transduction Inhibition

Broader (1)

tanespimycin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced cancer.
e14539 Background: Heat shock protein 90 (Hsp90) is a protein chaperone that regulates the proper folding, stability, and… 
2012
2012
The heat shock protein 90 inhibitor SNX-2112 inhibits B 16 melanoma cell growth in vitro and in vivo
SNX-2112 is a selective heat shock protein 90 (Hsp90) inhibitor which can exert a potent anticancer activity. In this study, we… 
Review
2011
Review
2011
Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer.
590 Background: Retaspimycin hydrochloride (IPI-504) is a potent, intravenously-administered heat shock protein 90 (Hsp90… 
2011
2011
The heat shock protein 90 inhibitor IPI-504 induces KIT degradation , tumor shrinkage and cell proliferation arrest in xenografts models of gastrointestinal stromal tumors
Giuseppe Floris, Maria Debiec-Rychter, Agnieszka Wozniak, Cristiana Stefan, Emmanuel Normant, Gavino Faa, Kathleen Machiels, Ulla… 
2011
2011
Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC).
7516 Background: IPI-504, a water-soluble analog of 17-allylamino-17-demethoxygeldanamycin (17-AAG), is an intravenously (IV… 
2011
2011
Abstract 2827: Activity of the proprietary Hsp90 inhibitor IPI-493 in models of colorectal cancer correlates with RAS pathway activation
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Heat shock protein 90 (Hsp90) plays a role in… 
2011
2011
Preclinical Development The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation , Tumor Shrinkage , and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors
The activity of the receptor tyrosine kinase KIT is crucial for gastrointestinal stromal tumor (GIST) growth and survival… 
2010
2010
28th Annual JPMorgan Healthcare Conference--Affymax and Infinity Pharmaceuticals.
The JP Morgan Healthcare Conference, held in San Francisco, included presentations by various pharmaceutical companies… 
2009
2009
A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel.
3547 Background: IPI-504 is a water-soluble heat shock protein 90 (Hsp90) inhibitor. IPI-504 causes the degradation of a variety… 
Review
2009
Review
2009
A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by…
8073 Background: IPI-504 (retaspimycin hydrochloride) is a potent, water-soluble heat shock protein 90 (Hsp90) inhibitor. IPI-504… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)